Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
This Review summarizes recent advances in biomarkers and therapies for Alzheimer disease—the products of decades of research—and discusses the challenges, gaps and clinical implications.
The current definition of myocardial infarction is applied inconsistently, with implications for patients and research; here, the authors propose a new definition and call for further research and consensus.
We performed gene therapy to induce expression of GDNF in the ventral tegmental area of rhesus monkey brains. Our approach countered the hypodopaminergic state that is associated with chronic alcohol drinking and reduced alcohol intake to fewer than two drinks per day while other ingestive behaviors remained intact. These findings, along with results from our ongoing clinical trials of GDNF gene therapy in other diseases, support future application of this approach in humans with alcohol-use disorder.
OncoNPC, a machine learning classifier developed to predict the primary origin of tumors, made confident predictions for over 40% of cancers of unknown primary (CUP) cases analyzed. Patients with CUP who had received site-specific treatments that retrospectively matched the OncoNPC predictions had better outcomes than patients who had been treated with discordant site-specific therapies. OncoNPC predictions doubled the number of patients with CUP who would be eligible for genomically guided therapies.
We transplanted gene-edited porcine hearts into two brain-dead human recipients, then evaluated their cardiac function and immune response over the following 66 hours. Both hearts showed sustained cardiac function over the course of the study, without evidence of hyperacute rejection or zoonotic transmission.
Alzheimer’s disease is a complex and chronic disease that evolves over decades. Proteomic analysis of cerebrospinal fluid from people with dominantly inherited forms of the disease reveals the temporal progression of pathological changes in Alzheimer’s disease and identifies extracellular matrix proteins as some of the earliest biomarkers of the disease.
Cost-effective fluid biomarkers for tau aggregate pathology would improve the diagnostic and prognostic work-up of Alzheimer’s disease and facilitate the discovery of anti-tau therapies. We identified MTBR-tau243 as a specific marker for tau aggregate pathology that could be implemented in clinical practice and trials.
Innovative clinical trial designs with a patient-centered mission are crucial to advancing modern cancer care; the adaptive phase 2 umbrella study CTONG1702 provides one model for this new era of trial design.
In individuals with anorexia nervosa, psilocybin therapy comes with specific risks and concerns; but an encouraging phase 1 trial underscores the necessity for more research into classic psychedelics to address the urgent need for effective treatments.
The authors generate a checklist of key considerations to guide patient and public involvement and engagement in future research, informed by lessons from the TLC study, which evaluated therapies for long COVID.
This study reveals that the production of cobalamin and succinyl-CoA is increased in the anal microbiome of patients with precancerous anal lesions. Testing for these two metabolites significantly improves diagnostic accuracy over standard cytology screening, which suggests potential for enhanced screening strategies for anal cancer.
Escalating severity and frequency of heatwaves have outpaced the effectiveness of existing prevention and adaptation measures; there is urgency for reassessment, enhancement and implementation of strategies to mitigate health impacts in dealing with this global health challenge.
A study investigates the links between fine-scale populations and outcomes including healthcare use and disease risk in a Los Angeles biobank, unveiling crucial insights into healthcare disparities in the USA.
This Review outlines three ‘grand challenges’ to protect and promote health in the face of climate change, and discusses the role of the health community in driving change within and beyond the health sector.
Multimorbidity is increasing globally, and addressing it requires a shift in the prevailing clinical, educational and scientific thinking. This Review discusses emerging mechanisms, research challenges and the implications for patients and healthcare systems.
Adverse childhood experiences can negatively impact lifelong health; this Review discusses the underlying mechanisms and potential solutions, advocating for multisectoral interventions and implementation research.
Artificial intelligence in combination with human expertise could be the optimal approach to improving diagnostic accuracy while maintaining a safety net in clinical imaging.
This review explains how large language models (LLMs), such as ChatGPT, are developed and discusses their strengths and limitations in the context of potential clinical applications.
